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BLISS is a versatile and quantitative method for
genome-wide proﬁling of DNA double-strand
breaks
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Bernd Zetsche1,5,6, Feng Zhang1,5,6,7, Magda Bienko4 & Nicola Crosetto4
Precisely measuring the location and frequency of DNA double-strand breaks (DSBs) along
the genome is instrumental to understanding genomic fragility, but current methods are
limited in versatility, sensitivity or practicality. Here we present Breaks Labeling In Situ and
Sequencing (BLISS), featuring the following: (1) direct labelling of DSBs in ﬁxed cells or tissue
sections on a solid surface; (2) low-input requirement by linear ampliﬁcation of tagged DSBs
by in vitro transcription; (3) quantiﬁcation of DSBs through unique molecular identiﬁers; and
(4) easy scalability and multiplexing. We apply BLISS to proﬁle endogenous and exogenous
DSBs in low-input samples of cancer cells, embryonic stem cells and liver tissue. We
demonstrate the sensitivity of BLISS by assessing the genome-wide off-target activity of two
CRISPR-associated RNA-guided endonucleases, Cas9 and Cpf1, observing that Cpf1 has
higher speciﬁcity than Cas9. Our results establish BLISS as a versatile, sensitive and efﬁcient
method for genome-wide DSB mapping in many applications.
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D
NA double-strand breaks (DSBs) are major DNA lesions
that form in a variety of physiological conditions—such as
transcription1,2, meiosis3 and VDJ recombination4—as
well as a consequence of exposure to DNA-damaging agents and
replication stress5. DSBs can also be induced in a controlled
manner at speciﬁc sites in the genome using programmable
nucleases, such as the CRISPR (clustered regularly interspaced
short palindromic repeats)-associated RNA-guided endonucleases,
Cas9 and Cpf1, which have greatly advanced genome editing.
However, the potentially mutagenic off-target DNA cleavage
activity of these nucleases represents an issue of major concern
that needs to be thoroughly assessed before these enzymes can be
safely used in the clinical setting6. Thus, developing methods that
can accurately map the genome-wide location of endogenous as
well as exogenous DSBs in different systems and conditions is not
only essential to advance our understanding of DSB biology,
but is also critical for successful translation of programmable
nucleases from research tools into clinical applications.
In the past few years, several methods based on next-
generation sequencing (NGS) have been developed to assess
DSBs at genomic scale, including chromatin immunoprecipita-
tion sequencing7,8, direct in situ breaks labeling, enrichment on
streptavidin and next-generation sequencing (BLESS)9–11,
genome-wide, unbiased identiﬁcation of DSBs enabled by seque-
ncing (GUIDE-seq)12, in vitro Cas9-digested whole-genome
sequencing (Digenome-seq)13, integrase-defective lentiviral vector
(IDLV)-mediated DNA break capture14, high-throughput,
genome-wide, translocation sequencing15 and more recently
End-Seq16 and DSBCapture17. Although all of these methods
represent important complementary tools to detect DSBs genome
wide (Supplementary Table 1), they also have important
drawbacks. For example, chromatin immunoprecipitation
sequencing of DSB-sensing or repair proteins such as p53-
binding protein 1 or the phosphorylated variant histone H2A.X
(gH2A.X) does not label DSBs directly and is unable to identify
DNA breakpoints with single-nucleotide resolution. GUIDEseq,
IDLV-mediated DNA break capture and high-throughput,
genome-wide, translocation sequencing detect DSBs by
quantifying the products of non-homologous end-joining repair,
potentially missing DSBs that are repaired through other pathways.
Furthermore, in vivo delivery of exogenous oligonucleotides in
GUIDEseq or viral cassettes in IDLV-mediated DNA break capture
for evaluating DSBs in primary cells and intact tissues may be
challenging. DSBs induced by programmable nucleases, such as
CRISPR-associated RNA-guided Cas9 and Cpf1, can be evaluated
in vitro using Digenome-seq, but this approach may not be
representative of relevant nuclease concentrations and of cellular
properties, such as chromatin environment and nuclear
architecture, which might inﬂuence the frequency of DNA
breaking and repair. Lastly, BLESS and the related methods End-
Seq16 and DSBCapture17 require substantial amounts of input
material (typically, in the order of millions of cells), are labour-
intensive and are semi-quantitative due to lack of appropriate
controls for PCR ampliﬁcation biases, limiting their applications
and scalability. Here we describe a method for breaks labeling
in situ and sequencing (BLISS) that compared with other DSB
mapping methods is more versatile, sensitive and quantitative. We
demonstrate the broad applicability of BLISS for genome-wide
detection of both endogenous and exogenous DSBs in low-input
samples of cells and tissues, as well as for genome-wide proﬁling of
on- and off-target DSBs introduced by Cas9 and Cpf1 nucleases.
Results
BLISS implementation and validation. A detailed workﬂow
of the BLISS method is depicted in Fig. 1a and a step-by-step
protocol can be found in Protocol Exchange18. Brieﬂy, the
procedure starts by attaching cells or tissue sections ﬁxed with
formaldehyde onto a microscope slide or coverglass, which
enables all the subsequent in situ reactions to be performed
without centrifugations, thus minimizing the risk of introducing
artiﬁcial DNA breaks and sample loss. DSBs are in situ blunted
and then ligated with a double-stranded DNA oligonucleotide
adapter containing the T7 promoter sequence, the RA5 Illumina
sequencing adapter, a random stretch of 8–12 nucleotides (nt)
that serves as unique molecular identiﬁer (UMI)19 and a sample
barcode suitable for multiplexing (Supplementary Fig. 1a and
Supplementary Data 1). Following genomic DNA (gDNA)
extraction, the sequence immediately downstream to the tagged
DSBs is linearly ampliﬁed via T7-mediated in vitro transcription,
which has been shown to introduce fewer biases compared
with exponential ampliﬁcation by PCR when amplifying
complementary DNA from low-input samples including single
cells20,21.
Overall, application of BLISS to various sample types and
preparations as described below yielded high-quality sequencing
libraries with a balanced UMI and strand composition
(Supplementary Fig. 1b–d). For most of the samples, we
performed single-end sequencing (Supplementary Data 2).
We developed a pre-processing pipeline that, by using the
information contained in the UMIs, ﬁlters out PCR duplicates
without the need for paired-end sequencing and counts DSB
events that have occurred at the same genomic location in
multiple cells (Supplementary Fig. 1e–g and Methods).
We ﬁrst tested whether BLISS can faithfully detect DSBs
occurring at deﬁned locations in the genome, even in low-input
samples of few thousand cells. We transfected HEK293 cells with
Streptococcus pyogenes Cas9 (SpCas9) and a single-guide RNA
(sgRNA) targeting the EMX1 gene. BLISS was able to precisely
localize and quantify both DSB ends generated by SpCas9 at the
correct on-target location (Fig. 1b). Furthermore, in low-input
samples of KBM7 cells, BLISS precisely identiﬁed telomeric ends,
which mimic DSB ends, and was able to reproduce the frequency
distribution of the 50 recessed telomeric ends previously identiﬁed
in a much larger number of cells using BLESS9 (Supplementary
Fig. 2a).
We then assessed the accuracy and quantitative power of BLISS
by sequencing at increasing depth three libraries obtained from
low-input samples of KBM7 cells (Supplementary Data 2). By
performing rarefaction analysis on the number of unique DSBs
labelled by UMIs that were detected at increasing sequencing
depths, we estimated that BLISS was able to detect 80–100 DSBs
per cell (Fig. 1c and Methods). This estimate was within the same
range of the number of gH2A.X foci quantiﬁed by microscopy in
the same cell line (85.7±60.6 foci per cell, mean±s.d.,
Supplementary Fig. 2b,c), suggesting that most of the DSBs
detected by BLISS represent true biological events rather than
background noise.
To further assess the quantitative ability of BLISS, we used
UMIs to count DSBs induced by the topoisomerase inhibitor,
etoposide. In two biological replicates of U2OS cells treated with
etoposide, the number of unique DSB ends detected by BLISS
increased in a dose-dependent manner, consistent with gH2A.X
measurements (Supplementary Fig. 3a–c). The treatment resulted
in DSB accumulation at recurrent genomic locations in multiple
cells, which could be distinguished thanks to the fact that multiple
DSB ends mapping to the same location were labelled by distinct
UMIs (Fig. 1d and Supplementary Fig. 3d,e). These recurrent
locations were signiﬁcantly enriched in the neighborhood of
transcriptional start sites (TSS), conﬁrming prior ﬁndings by
BLESS that etoposide has prominent effects around TSS22 (Fig. 1e
and Supplementary Fig. 3f).
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Proﬁling of endogenous DSBs in primary cells and tissue. The
ability to obtain genome-wide DSB maps from primary cells and
tissue samples would greatly help studies of DNA damage and
repair processes in animal models and clinical samples. With this
goal in mind, we performed proof-of-principle experiments using
either tissue sections or puriﬁed nuclei derived from mouse liver
biopsies (Supplementary Fig. 4a,b). In line with recent ﬁndings in
different cell types1,2,17, DSBs were strongly enriched in the
neighbourhood of the TSS, as well as along the gene body of
highly expressed genes (Fig. 1f–h and Supplementary Fig. 4c–e).
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Figure 1 | Quantitative detection of natural and etoposide-induced DSBs. (a) Schematic of BLISS. The workﬂow starts by either ﬁxing cells onto a
microscope slide or in a multi-well plate, or by immobilizing already ﬁxed tissue sections onto a slide. DSB ends are then in situ blunted and tagged with
dsDNA adapters containing components described in the boxed legend and in Supplementary Data 1. Tagged DSB ends are linearly ampliﬁed using in vitro
transcription and the resulting RNA is used for Illumina library preparation and sequencing. (b) BLISS reads aligned to an SpCas9 on-target cut site
(arrowhead) in the EMX1 gene. Light blue, guide sequence. Orange, PAM sequence. Dark blue, reads mapped to the minus strand. Red, reads mapped to the
plus strand. (c) Estimated number of DSBs per cell in three replicates sequenced at increasing sequencing depth. Dashed line, hyperbolic interpolation.
(d) Number of DSB locations in etoposide-treated versus control U2OS cells by ﬁltering on the minimum number of UMIs per DSB location. (e) Fraction of
DSB locations mapped around the transcription start sites (TSS) in control versus etoposide-treated U2OS cells as a function of the minimum number of
UMIs per DSB location. Dashed lines, linear interpolation. Colour shades, 95% conﬁdence intervals. (f) For BLISS on mouse liver, mapping of sequenced
DSB ends found in the top 10% (red) and bottom 10% (blue) of expressed genes in the mouse liver. n, number of biological replicates. Dots, mean value.
Whiskers, min-max range. Dashed lines, spline interpolation. (g) Percentage of sequenced DSB ends mapped in a±1 kb interval around the TSS for each
inter-decile interval of gene expression in mouse liver. FPKM, fragments per kilobase of transcript per million mapped reads. n, number of biological
replicates. Bars, mean value. Whiskers, min–max range. (h) Number of sequenced DSB ends mapped per kilobase inside the gene body of the top 10% and
bottom 10% expressed genes in mouse liver. n, number of biological replicates. Whiskers, 2.5–97.5 percentile range. P, Mann–Whitney test.
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Gene Ontology analysis of those genes that were reproducibly
identiﬁed as carrying the highest DSB levels in three biological
replicates revealed a signiﬁcant enrichment in functional terms
related to liver-speciﬁc metabolic processes, indicating that BLISS
is able to capture endogenous DSBs related to tissue-speciﬁc
processes (Supplementary Fig. 4f and Supplementary Data 3
and 4). A similar enrichment of DSBs in the neighbourhood of
the TSS and along the gene body of highly expressed genes was
also recapitulated in low-input samples of primary mouse
embryonic stem cells (mESCs) (Supplementary Fig. 4g–i),
conﬁrming that BLISS is a highly versatile method that can be
applied to study endogenous DSBs in various cell and tissue
samples. Furthermore, we assessed chromatin accessibility in liver
tissue sections adjacent to those processed by BLISS, by applying
a modiﬁed BLISS protocol in which artiﬁcial DNA breaks are ﬁrst
introduced in situ by the HindIII restriction endonuclease
(Supplementary Fig. 5a,b, Methods and Protocol Exchange18.
This revealed that, although endogenous DSBs mapped by BLISS
were enriched in the open chromatin regions characterized by a
high frequency of HindIII cuts, in analogy to previous
ﬁndings16,17, many genomic regions with similar chromatin
accessibility had very different DSB levels and vice versa
(Supplementary Fig. 5c).
Proﬁling of Cas9 and Cpf1 speciﬁcity. We next aimed to assess
the sensitivity of BLISS by characterizing the DSBs induced by
Cas9 and Cpf1. Evaluating Cas9 and Cpf1 on- and off-targets is a
valuable way of assessing BLISS sensitivity, because the nuclease-
induced cleavage sites (1) are sparse enough so as to not saturate
BLISS; (2) are relatively well-deﬁned by both location of cut sites
found by other assays12,13 and the observation that off-targets
generally have homology to the on-target guide9–13; and (3) occur
over a wide dynamic range of DSB frequencies to allow
quantiﬁcation of the detection sensitivity. Meanwhile, BLISS is
a versatile and minimally disruptive technique for studying the
speciﬁcity of CRISPR nucleases, as by labelling DSBs post ﬁxation
it requires no additional perturbations to the cell beyond delivery
of the nuclease and RNA guide. Hence, we developed a workﬂow
to screen the off-target activity of Cas9 or Cpf1 endonucleases
using BLISS (Cas9-BLISS and Cpf1-BLISS) in parallel with
existing genome-editing protocols (Supplementary Fig. 6a). Aside
from culturing cells for BLISS on poly-D-lysine-coated plates and
ﬁxation 24 h post transfection, no additional modiﬁcations of
delivery reagents or workﬂows were necessary, allowing BLISS to
capture a snapshot of the CRISPR nuclease activity in cells with
minimal bias.
To benchmark the sensitivity of Cas9-BLISS against existing
genome-wide speciﬁcity methods such as BLESS, GUIDEseq and
Digenome-seq, we transfected HEK293 cells with SpCas9 and two
sgRNAs targeting the EMX1 and VEGFA genes, both of which
have been characterized using all three methods11,12,14–15. This
set of known off-targets allowed us to further optimize Cas9-
BLISS through direct comparison of different DSB labelling
strategies, showing that in situ A-tailing before adapter ligation
increases the sensitivity of DSB detection when directly compared
with the original blunt end ligation chemistry (Supplementary
Fig. 6b–e). Furthermore, to achieve greater sensitivity we reﬁned
the computational pipeline that we previously established for
identifying bona ﬁde Cas9 DSBs for the analysis of Cas9-BLESS
data10 (Methods). In addition to the expected on-target DSB sites,
BLISS detected numerous off-target sites that were successfully
validated by targeted NGS, including many sites previously
identiﬁed by BLESS, GUIDEseq or Digenome-seq (Fig. 2a and
Supplementary Data 5). BLISS also uncovered numerous new off-
target sites that were not found in BLESS, even when the reﬁned
computational pipeline was re-applied to published BLESS data
on the same targets11 (Fig. 2b). Side-by-side comparison of BLISS
with Digenome-seq and GUIDEseq revealed that although all the
three methods generally agree on the top off-targets identiﬁed,
they differ in the number of weaker off-target sites, particularly in
the case of VEGFA (Fig. 2c).
We next applied BLISS to characterize the DNA-targeting
speciﬁcity of Cpf1 (Cpf1-BLISS). Cpf1 is a two-component
RNA-programmable DNA nuclease with several unique proper-
ties that may broaden the applications of genome engineering:
(1) it employs a short CRISPR RNA without an additional trans-
activating CRISPR RNA; (2) it utilizes a T-rich protospacer-
adjacent motif (PAM) located 50 to the target sequence; and (3) it
generates a staggered cut with a 50-overhang23. We selected six
Cpf1 targets across four different genes for genome-wide
off-target evaluation using BLISS and targeted NGS. Four
targets have NGG PAMs on the 30-end to enable a
simultaneous comparison between SpCas9 and eSpCas9. We
evaluated Cpf1 from Acidaminococcus sp. (AsCpf1) and
Lachnospiraceae bacterium (LbCpf1), both of which have been
harnessed for efﬁcient mammalian genome editing23. At the dual
Cpf1 and Cas9 targeted loci, BLISS revealed differences in the
in vivo pattern of DSBs induced by these two enzymes. Taking the
histogram of all the differences between reads mapping to
the opposite sides of the DSBs (Supplementary Fig. 7a) showed
that although Cas9 cuts are generally blunt ended or contain 1 nt
overhangs, Cpf1 cuts exhibit a wide distribution of overhang
lengths depending on the target (Supplementary Fig. 7b).
Although in vitro cleavage of AsCpf1 and LbCpf1 produces
4–5 nt 50-overhangs as the predominant cleavage outcome23,
these results suggest that in vivo processing of Cpf1 cut sites
generates more heterogeneous DSB patterns.
To identify Cpf1 off-target sites using BLISS, we applied the
same computational pipeline as was used for Cas9-BLISS. To
maximize sensitivity, we performed targeted NGS on all the off-
target sites that were identiﬁed in independent BLISS biological
replicates from both AsCpf1 and LbCpf1 (Supplementary Fig. 8).
Comparing the BLISS results for AsCpf1 or LbCpf1 with SpCas9,
we consistently found fewer bona ﬁde off-target sites for the two
Cpf1 orthologues (Fig. 3a and Supplementary Fig. 8), suggesting
that Cpf1 is less tolerant of mismatches than Cas9. For the four
targets with shared Cpf1 and Cas9 PAMs, genome modiﬁcation
with SpCas9 yielded a greater range of bona ﬁde off-target sites
(Supplementary Fig. 9), consistent with prior observations that
individual SpCas9 guides can have a wide variation in the number
of off-target sites independent of the prevalence of closely
matched sites in the genome12. As expected, the use of eSpCas9
(ref. 11) reduced the number of off-targets without loss of
on-target activity. Lastly, to assess whether BLISS is sensitive
enough to detect a large number of Cpf1-induced breaks across a
wide dynamic range of cleavage activity, we designed additional
guides for Cpf1, targeting repetitive sequences with 278 (GRIN2b
repetitive guide) and 8,130 (DNMT1 repetitive guide) perfectly
matched on-target sites with a TTTN PAM, as predicted using
Cas-OFFinder24. A wide range of both on- and off-target loci
were detected using Cpf1-BLISS (Supplementary Fig. 10),
suggesting that the speciﬁcity of Cpf1 determined using BLISS
was not an artefact of BLISS, and that Cpf1 can indeed have a
high level of speciﬁcity for guides not targeting repetitive regions.
Altogether, these results corroborate the ﬁndings of other recent
studies that Cpf1 can be highly speciﬁc25,26.
The Cpf1 repetitive targets also enabled us to study the position
dependence of mismatch tolerance by examining whether
mismatches in certain positions are enriched in the off-target
results versus the genomic background. In particular, the DNMT1
repetitive guide has nearly 37,000 off-targets with a single
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mismatch to the on-target sequence and a TTTN PAM, according
to Cas-OFFinder24. Each mismatched position is represented in
at least 150 genomic loci, although the prevalence of a mismatch
at a given target position is not uniformly distributed (Fig. 3b,c).
Cpf1-BLISS detected B1,000 and B3,600 off-targets for AsCpf1
and LbCpf1, respectively, which contain only one mismatch to
the on-target sequence. The fraction of Cpf1-BLISS-detected sites
over all possible mismatches at that position was calculated to
obtain a measure of how permissive Cpf1 is to mismatches along
the guide (Fig. 3c). We also systematically introduced mismatches
between the Cpf1 guide and target DNA, normalizing the
on-target modiﬁcation rate for each mismatched guide to
the matched target (Fig. 3d and Supplementary Fig. 11). The
on-target indel data from the mismatched guides were used to
generate a composite model of the mismatch tolerance versus
position for AsCpf1 and LbCpf1, with the overlaid SpCas9 trace
based on reanalysis of previous mismatch data27 (Fig. 3e and
Methods). Taken together, there appears to be three regions of the
guide for both AsCpf1 and LbCpf1 where mismatches are more
tolerated: (1) at the 30-PAM distal end of the guide (positions
19–20); (2) towards the middle of the guide (positions 8–11); and,
to a lesser degree, (3) at the ﬁrst base at the 50-PAM proximal end
n.d.
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(position 1). This qualitatively suggests that Cpf1 may have
several distinct regions of the guide that enforce complementarity
and thereby contribute to its heightened speciﬁcity compared
with SpCas9.
Discussion
We developed a versatile, sensitive and quantitative method for
direct genome-wide DSB proﬁling that is applicable to low-input
samples of both cells and tissue, and is easily scalable for high-
throughput DSB mapping in many samples. BLISS offers several
unique features and advantages compared with the existing
methods for genome-wide DSB detection: (1) robust discrimina-
tion of DSB events that occurred at the same genomic location in
multiple cells or alleles, by using UMIs to ﬁlter out PCR
duplicates; (2) applicability to low-input samples of cells and
tissue sections, by performing all in situ reactions and washes on a
solid surface; (3) assay scalability and cost-effective multiplexing
by performing in situ reactions inside multi-well plates and
barcoding samples in different wells before pooling; and (4) fast
BLISSa
b c
d e
Targeted NGS
% Indel
Targeted NGS
% Indel
1 5 10 2015
LbCpf1
SpCas9
AsCpf1
1
Genomic off targets with
1 bp mismatch from BLISS
5 10 2015
0
5,000
10,000
15,000
20,000
25,000
0.0
0.1
0.2
0.3
BL
IS
S 
de
te
ct
ed
 / 
Al
l 1
 b
p 
M
M AsCpf1 (n = 1,062)
G
en
om
ic 
co
un
t o
f 1
 b
p 
M
M
  Genomic 1 bp MM withTTTN PAM  (n = 36,777)LbCpf1 (n = 3,603)
0 1 2 3 4 5 5 35 65 95
DNMT1-3
% Indel
0 1 2 3 4 5 5 35 65 95
0 1 2 3 4 5 5 35 65 95
DNMT1-4
0 1 2 3 4 5 5 35 65 95
0 1 2 3 4 5 5 35 65 95
0 1 2 3 4 5 5 35 65 95
EMX1-4
Bio1
Bio2
Bio1
Bio2
AsCpf1 LbCpf1
AsCpf1 LbCpf1
AsCpf1 LbCpf1
AsCpf1 LbCpf1
BLISS
Bio1
Bio2
Bio1
Bio2
Bio1
Bio2
Bio1
Bio2
EMX1-2
GRIN2b-7
Bio1
Bio2
Bio1
Bio2
Bio1
Bio2
Bio1
Bio2
Bio1
Bio2
Bio1
Bio2
VEGFA-8
LbCpf1
AsCpf1
% Indel
0.1 1 10
AsCpf1 LbCpf1
AsCpf1 LbCpf1 % Indel
% Indel
% Indel
Position:
20 bp on target locus
crRNA
Repetitive target
5′
3′
5′
3′
-3′
-3′
-5′
-3′
-3′
-5′
-5′
crRNA
crRNAs with
1 bp mismatch
-5′
5′ - - 3′
Position along 20 bp guide sequence
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Co
m
po
sit
e 
m
ism
at
ch
 to
le
ra
nc
e
Position:
15′ - - 3′2 4 6 8 10 12 14 16 18 20
2 4 6 8 10 12 14 16 18 20
Position along 20 bp guide sequence
1
Unique DSB ends per 105 reads
PAM
PAM
Cpf1 PAM
Cpf1 PAM Cas9 PAM
Figure 3 | Characterization of AsCpf1 and LbCpf1 speciﬁcity. (a) Validated on- and off-target sites for AsCpf1 and LbCpf1 for six separate guide targets as
measured by Cpf1-BLISS over two independent biological replicates and validated by targeted NGS (n¼ 3, error bars show s.e.m.). Grey boxes indicate
DSB loci not detected within a biological replicate. (b) Evaluating the position-dependent mismatch tolerance of AsCpf1 and LbCpf1 using a repetitive guide
with 36,777 predicted genomic loci with single mismatches. (c) A map of mismatch tolerance per position generated by dividing at each base the number
of off-targets discovered in BLISS versus the possible single mismatched genomic targets for Cpf1. The grey line plotted on the left y axis is the count of
single mismatched targets in the genome for Cpf1 as predicted by Cas OFFinder24. (d) Guide designs for investigating the effect of single base pair
mismatches in the RNA guide on AsCpf1 and LbCpf1 speciﬁcity by measuring the change in their on-target efﬁciency versus a matched guide.
(e) Composite mismatch tolerance model for AsCpf1 and LbCpf1 based on saturated single base pair mismatches for two guides. Cas9 data (green)
modelled from existing Cas9 single mismatch data27.
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turnaround time compared with BLESS (B12 active work-hours
over 5 days to process 24 samples by BLISS versus at least
60 active work-hours over 15 days by BLESS). In addition,
we demonstrate that BLISS is a highly sensitive method to
assess the speciﬁcity of CRISPR-associated RNA-guided DNA
endonucleases Cas9 and Cpf1, and we show that, in agreement
with previous reports25,26, Cpf1 can provide high levels of editing
speciﬁcity. In conclusion, BLISS is a powerful and versatile
method for genome-wide DSB proﬁling that we believe will
catalyse efforts to proﬁle natural and artiﬁcially induced DSBs in
many conditions and sample types.
Methods
Cells and tissues. The following cell lines were used: KBM7 from Oscar
Fernandez-Capetillo (SciLifeLab, Stockholm, Sweden); U2OS from Mats Nilsson
(SciLifeLab); HEK 293 from ATCC (although this cell line is catalogued as a
commonly misidentiﬁed cell line in the ICLAC database (http://iclac.org/databases/
cross-contaminations), we used it for CRISPR experiments, as it is easy to culture
and can be efﬁciently transfected); mESCs from Simon Elsaesser (SciLifeLab).
None of the cell lines was authenticated. Culturing conditions were as following:
KBM7 in Iscove’s modiﬁed Dulbecco’s medium (Life Technologies, catalogue
number 10829018), supplemented with 10% fetal bovine serum (FBS, Gibco,
catalogue number F2442); U2OS in DMEM medium (Life Technologies, catalogue
number D0819), supplemented with 10% FBS; HEK 293 T in DMEM supple-
mented with 10% FBS; and mESCs in minimal essential medium (Sigma, catalogue
number M2279), supplemented with 20% FBS, 1% GlutaMAX (Gibco, catalogue
number 35050061), 1% non-essential amino acids (Gibco, catalogue number
11140035), 1% sodium pyruvate (Gibco, catalogue number 11360070) and 0.2%
b-mercaptoethanol, in the presence of leukaemia inhibitory factor (Sigma catalogue
number L5158-5UG) corresponding to 1,000Uml–1. All cell lines were tested to be
mycoplasma free using MycoAlert Mycoplasma Detection Kit (Lonza, catalogue
number LT07-118). For tissue-BLISS on mouse liver, wild-type, 6-week-old
C57/BL6 male mice were killed following the guidelines in the MIT protocol
0414-027-17 ‘Modeling and Treating Genetic Disease Using Targeted Genome
Engineering’ (IACUC AWA A3125-01, IACUC 0411-040-14, approval date
5/16/2013).
Cas or Cpf1 expression constructs and transfections. The selected targets for
Cas9-BLISS are located within the EMX1 locus (50-GAGTCCGAGCAGAAGAA
GAAgGG-30) and the VEGFA gene locus (50-GGTGAGTGAGTGTGTGCGTG
tGG-30). The plasmids used containing the SpCas9 and the sgRNA cassette were
identical to the ones used for Cas9-BLESS11, where the targets were labelled as
EMX1(1) and VEGFA(1). The same targets have also been studied using
GUIDEseq12, where they were labelled as EMX1 and VEGFA_site3. AsCpf1 and
LbCpf1 along with their cognate CRISPR RNAs were cloned into the same
expression vector as Cas9, to enable a direct comparison. Cells were plated before
transfection in 24-well plates pre-coated with poly-D-lysine (Merck Millipore,
catalogue number A003E) at a density ofB125,000 per well and were let grow for
16–18 h until 60–70% conﬂuence. For transfections, we used 2 ml of Lipofectamine
2000 (Life Technologies, catalogue number 11668019) and 500 ng of Cas9 plasmid
in 100ml total of OptiMEM (Gibco, catalogue number 31985062) per each well of a
24-well plate.
Immunoﬂuorescence staining. gH2A.X immunostaining was performed using a
mouse anti-phospho-histone H2A.X (ser139) primary antibody (Millipore,
catalogue number 05-636) diluted 1:1,000 in blocking buffer and a goat anti-mouse
IgG (Hþ L) Alexa Fluor 647 conjugate (Thermo, catalogue number A-21235)
secondary antibody diluted 1:1,000 in blocking buffer. To image gH2A.X foci,
we acquired images every 0.4 mm throughout the entire nuclear volume using a
 40 oil objective and an LSM 780 confocal microscope (Zeiss).
BLISS adapters. All BLISS adapters were prepared by annealing two
complementary oligonucleotides as described below. All oligos were purchased
from Integrated DNA Technologies as standard desalted oligos. UMIs were
generated by random incorporation of the four standard dNTPs using the
‘Machine mixing’ option. Before annealing, sense oligos diluted at 10 mM in
nuclease-free water were phosphorylated for 1 h at 37 C with 0.2 U ml–1 of T4
Polynucleotide Kinase (NEB, catalogue number M0201). Phosphorylated sense
oligos were annealed with the corresponding antisense oligos pre-diluted at 10 mM
in nuclease-free water, by incubating them for 5min at 95 C, followed by gradual
cooling down to 25 C over a period of 45min (1.55 Cmin 1) in a PCR
thermocycler.
BLISS sample preparation. A step-by-step BLISS protocol is provided in Protocol
Exchange18. For BLISS in cell lines, we typically either grew cells directly onto
13mm coverslips (VWR, catalogue number 631-0148) or we spotted them onto
coverslips pre-coated with poly-L-lysine (Sigma, catalogue number P8920-100ML).
For Cas9 and Cpf1 experiments, we ﬁxed HEK293T cells directly into the 24-well
plate used for transfections and performed all in situ reactions directly inside the
wells of the plate. For BLISS in mouse liver, we developed two approaches: (1)
Tissue cryopreservation and sectioning: freshly extracted liver biopsies were ﬁrst
ﬁxed in paraformaldehyde 4% for 1 h at 25 C and then immersed in a sucrose
solution (15% overnight and then 30% until the tissue sank) before embedding in
optimal cutting temperature medium (OCT). Thirty-micrometre-thick tissue
sections were mounted onto microscope slides, dried for 60min at room
temperature (rt) and stored at 4 C before further processing. (2) Preparation of
nuclei suspensions: freshly extracted liver biopsies were cut into small pieces and
transferred into a 1.5–2ml tube containing nucleus isolation buffer (NaCl 146mM,
Tris-HCl 10mM, CaCl2 1mM, MgCl2 21mM, bovine serum albumin 0.05%,
Nonidet P-40 0.2% pH 7.8). We typically incubated the samples for 15–40min
until the tissue fragments became transparent, after which the nuclei were
centrifuged for 5min at 500 g and then re-suspended in 200–500 ml of 1 PBS.
One hundred microlitres of nuclei suspension were dispensed onto a 13mm
diameter poly-L-lysine-coated coverslip and incubated for 10min at rt. Afterwards,
100 ml of paraformaldehyde 8% in 1 PBS were gently added and incubated for
10min at rt, followed by two washes in 1 PBS at rt. The samples were stored in
1 PBS at 4 C up to 1 month before performing BLISS.
In situ DNA digestion. Samples for DNA accessibility mapping were prepared in
the same way as BLISS samples, except that the in situ DSBs blunting step
was substituted by an in situ DNA digestion step using 1U ml–1 of HindIII
endonuclease (NEB, catalogue number R3104) and incubating the samples for 18 h
at 37 C. HindIII cut sites were ligated with modiﬁed BLISS adapters carrying the
HindIII complementary sticky end (see Supplementary Fig. 4h). To prevent in situ
re-ligation of HindIII cut sites, the samples were incubated for 2 h at 37 C in the
presence of 0.015U ml–1 of calf intestinal alkaline phosphatase (Promega, catalogue
number M2825) before in situ ligation.
Image processing and counting of cH2AX foci and cells. All algorithms were
implemented in MATLAB using custom-made scripts, available upon request.
To count gH2AX foci in KBM7 cells, we ﬁrst segmented nuclei stained with
4,6-diamidino-2-phenylindole using image thresholding. We then identiﬁed all
local maxima within each image and then ranked the maxima according to their
response to a Laplacian ﬁlter. We then ﬁtted a Gaussian to the ﬁrst peak of the
histogram of the ﬁlter responses, corresponding to background noise (that is,
autoﬂuorescence and photon noise). We counted gH2AX foci per nucleus using the
dots with a ﬁlter response of more than 10 s.d. above the mean of the background.
To count cells before capture and gDNA extraction, we ﬁrst rinsed samples in
nuclease-free water, air dried them and acquired wide-ﬁeld images of areas selected
for cell capture using a TI-S-E Motorized stage operated by NIS-Elements software
(Nikon). Next, we identiﬁed objects in wide-ﬁeld images by locating maxima of the
determinant of the gradient structure tensor. We then classiﬁed objects being cells
or not based on anisotropy, size and median gradient magnitude. Finally, we
manually corrected and veriﬁed the segmentation.
Pre-processing of sequencing data. To convert the raw sequencing data into
BED ﬁles ready to be used for ad hoc analyses, we applied the pipeline summarized
in Supplementary Fig. 1e. Brieﬂy, we ﬁltered the FASTQ ﬁles for overall quality by
requiring a Phred score Z30 for every base. Thereafter, we scanned the ﬁltered
reads for the presence of the exact preﬁx (8N UMI and sample barcode), by
allowing up to two mismatches in the UMI portion and up to one mismatch in the
barcode (see analysis of UMI errors below). After removal of the preﬁx, we aligned
the reads to the reference genome (GRCh37/hg19 for human, NCBI37/mm9 for
mouse). We retained reads mapping with a quality score Z5, after excluding
regions with poor mappability. Next, we performed a further ﬁltering step based on
UMI sequences to ﬁlter out PCR duplicates. Reads mapping in nearby locations
(at most 8 nt apart) and having at most two mismatches in the UMI sequence were
associated with the location of the most frequent read in the neighbourhood.
Finally, we generated BED ﬁles containing a list of genomic locations associated
with unique UMIs to be used in downstream analyses.
UMI error model. In BLISS, the incorporation of UMIs at the site of in situ DSB
ligation enables distinguishing breaks occurring at the same nucleotide position in
different alleles or cells. However, during ampliﬁcation by in vitro transcription
and PCR, as well as during sequencing, the original UMI sequence may be subject
to errors that in turn can cause both false positive (the same DSB labelled by two
different UMIs) and false negative (two distinct DSB events labelled by the same
UMI) errors. It is therefore important to implement an error-correction scheme
that aims to maximize the number of unique DSB events identiﬁed, while
minimizing the number of false-positive DSB callings. To do so, we ﬁrst performed
an experiment in which we in situ digested gDNA using a restriction enzyme
(HindIII), followed by in situ ligation of the modiﬁed BLISS adapter shown in
Supplementary Fig. 1f. Thus, in this experiment, R1 reads are expected to start with
the 8 nt ﬁxed UMI sequence, 50-GTCGTCGC-30 followed by the 6 nt HindIII
recognition sequence, 50-AAGCTT-30 . To assess the error rates associated with
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ampliﬁcation and sequencing, we considered for simplicity only mismatch errors.
We ﬁrst ﬁltered the FASTQ ﬁle by selecting all the strings of 8 bp found before the
AAGCTT sequence (allowing for 1 mismatch). Then, we counted how many of
these strings contain up to eight mismatches in the ﬁxed UMI sequence. As shown
in Supplementary Fig. 1g, most reads (B77%) had 0 mismatches in the UMI
sequence, whereas B16% had 1 mismatch. Importantly, grouping together faulty
UMIs with 1 or 2 mismatches takes into account 90% of the mismatch errors,
indicating that counting as distinct DSB ends the R1 reads that map to the same
genomic location and tagged with UMIs differing for at least 2 nt is a reliable
procedure.
To further corroborate these observations, we performed one additional
experiment in which we in vitro transcribed a synthetic DNA fragment purchased
from Integrated DNA Technologies as gBlocks Gene Fragments, containing
(from 50): the T7 promoter sequence; the Illumina RA5 adapter sequence; the 16 nt
sequence 50-GTCGTATCGTCGTTCC-30 representing a ‘ﬁxed’ UMI, the HindIII
cutting site 50-AAGCTT-30 and 469 nt taken from the ampicillin resistance open
reading frame. Out of 1,900,898 reads obtained, 1,274,568 (67%) had at most 1
mismatch in the HindIII recognition site location and were preceded by 16 nt,
as expected. Of these, 1,273,545 (99.9%) reads had at most 1 mismatch in the 8 nt
preceding the cut site. Therefore, by ﬁltering the initial FASTQ ﬁle for a preﬁx of
the form UMI-barcode[1,0,0]-cutsite[1,0,0] (numbers in square brackets indicate
the allowed number of mismatches, insertions and deletions, respectively), we
might lose at most 30% of the sequenced reads. This percentage is not signiﬁcantly
lowered by allowing for more mismatches in the cutsite location or in the barcode
location. We note that taking into account small insertions and deletions (indels)
might reduce the number of reads ﬁltered out. However, accounting for indels in
the error model would make downstream read identiﬁcation more ambiguous.
Hence, we decided to stick to an error model that is more stringent, but more
robust to false positive errors. In conclusion, for all the data sets presented in the
paper, we ﬁltered FASTQ ﬁles based on the preﬁx: UMI[2,0,0]-barcode.
Identiﬁcation of telomeric ends. To analyse the composition of BLISS reads
derived from the telomeric C-rich strand, we screened R1 reads with the correct
preﬁx (8N UMI and sample barcode) for the presence of each of the six possible
patterns based on the human telomeric sequence: [#A,#AA,#TAA,#CTAA,#CC
TAA,#CCCTAA]-CCCTAA.
Estimation of DSBs per cell. To estimate the number of spontaneous DSBs, we
sequenced at different depth three libraries prepared from small numbers of KBM7
cells (L1, L3 and L4, see Supplementary Data 2). For each sample, we estimated the
number of DSBs per cell by counting the number of sequenced reads with correct
preﬁx mapped to a unique genomic location and tagged by a unique UMI and
assuming that on average one DSB produces two unique reads. We then ﬁtted the
data to the model DSB ¼ rDSBmaxrþ k , where DSBmax is the number of DSB events per
cell at saturation, r is the number of total reads and k is a constant. At saturation,
the model estimated DSBmax¼ 94 breaks per cell (95% conﬁdence interval:
93.10–95.07), in agreement with gH2A.X foci counting in the same cell line
(Supplementary Fig. 2c).
Quantiﬁcation of etoposide effects. For U2OS cells treated with etoposide, we
counted the number n of unique DSB locations on each chromosome that were
found with at least 1rtr10 UMIs and at most t¼ 500 UMIs. We then normalized
the cumulative sum, n by the total number of DSB ends sequenced and calculated
the ratio between the normalized cumulative sum in the treated and non-treated
sample, and averaged the fold change over all chromosomes. We repeated the same
process separately for the unique locations exclusively found in the etoposide-
treated or untreated sample. For enrichment analysis of etoposide-induced DSBs
around the TSS, we calculated the fraction of unique DSB locations (found with at
least 1rtr10 UMIs and at most t¼ 500 UMIs) that fell in a window of ±5 kb
centred on the TSS of all genes.
Quantiﬁcation of DSBs near TSS and within gene bodies. For mouse liver and
mESCs, we used RNA-seq data obtained from the Mouse Encode Project at Ren lab
(http://chromosome.sdsc.edu/mouse/download.html). We ﬁrst identiﬁed the top
10% and bottom 10% expressed genes and then, for each gene in the two groups,
we calculated the number of unique DSB ends (that is, the number of DSB
locations on either strand associated with a unique UMI) falling in an interval of
±5 kb centred on the TSS of the gene. This approach enabled us to distinguish
DSBs that had occurred at the same genomic location in different cells. We then
calculated the proportion of all the DSB locations mapped around the TSS of both
top 10% and bottom 10% expressed genes, that fell in a given distance interval near
the TSS. For gene bodies, we performed a similar analysis by counting all the
unique DSB ends mapped within the gene body of the top 10% and bottom 10%
expressed genes, and normalizing the counts by gene length.
Gene ontology analysis of top fragile genes. We identiﬁed top 10% fragile genes
in three biological replicates of mouse liver tissue sections either based on the
number of unique DSB ends mapped in a±1 kb interval centered on the TSS of all
genes or based on the number of unique DSB ends mapped within the gene bodies.
We performed GO process analysis of the fragile genes identiﬁed in all the three
biological replicates, using the publicly available web-based Gorilla tool (http://
bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-10-48).
Identiﬁcation of Cas9 and Cpf1 on- and off-target DSBs. We updated the
original DSB detection pipeline for analysing Cas9-BLESS data9,10 to determine
whether we could enhance the sensitivity of off-target detection by both BLESS and
BLISS. Previously, we demonstrated that a homology search algorithm was capable
of separating bona ﬁde Cas9-induced DSBs from background DSBs and performed
the analysis on the top 200 DSB loci with the strongest signal after initial
ﬁltering10,11. To achieve even greater sensitivity, here we extended this homology
search to the top 5,000 DSB locations identiﬁed by BLISS. To enable a direct
comparison between BLESS and BLISS, we used this updated approach to
re-analyse the BLESS data previously obtained with wild-type SpCas9 (ref. 11)
on the same EMX and VEGFA guide targets as studied here. Brieﬂy, a ‘Guide
Homology Score’ was determined using an algorithm that searched for the
best-matched guide sequence within a region of the genome 50 nt on either side of
the centre of a DSB cluster identiﬁed in BLESS/BLISS for all NGG and NAG PAM
sequences in the case of SpCas9 (ref. 11) and all possible PAMs in the case of
AsCpf1 and LbCpf1 for maximum sensitivity. A score based on the homology was
calculated using the Pairwise2 module in the Biopython Python package with the
following weights: a match between the sgRNA and the genomic sequence scores
þ 3, a mismatch is  1, whereas an insertion or deletion between the sgRNA and
genomic sequence costs  5. Thereby, an on-target sequence with the fully
matched 20 bp guide would have a Guide Homology Score of 60. Previously,
we included the PAM match in the scoring, yielding a maximum score of 69, but to
make the score more versatile and comparable across different PAMs, we removed
the PAM dependence in the scoring. Using this guide homology score, we
performed a receiver operating characteristic curve analysis based on validated and
non-validated off-targets from SpCas9-BLESS10, which justiﬁed our previous
choice of a homology score cutoff (41 out of a max score of 60), to maximize the
sensitivity and speciﬁcity of Cas9-BLISS and Cpf1-BLISS. In practical terms, this
score corresponds tor4 mismatches orr2 gaps, as well as combinations thereof.
Modelling mismatch tolerance per-position of Cas9/Cpf1. Analysis of tolerance
to mismatches at different positions along target/sgRNA duplex. The cutting fre-
quency of Cas9/Cpf1 at a target with a single mismatch is modelled as
fmut x; gð Þ¼fwt gð Þ  t x0ð Þþ a gð Þþ Eð Þ;
where fmut x; gð Þ represents the cutting frequency with sgRNA g at the target that
has a mismatch to the sgRNA at position x, fwt gð Þ represents the cutting frequency
with sgRNA g at its perfectly matching target, t(x0) denotes the tolerance of
mismatch at position x0 , a(g) represents the effect of sgRNA g speciﬁc properties
on the mismatch tolerance (properties such as transfection efﬁciency, melting
temperature, secondary structure and so on) and E represents experimental
variation. The position x on the sgRNA may, in reality, shift to position x0 due to
stretch or compression of the sgRNA-target DNA hetero-duplex. The amount of
shift can be different for different sgRNA, mismatch pairing and positions. This
effect is termed ‘wobbling’. Given the measured cutting frequency fmut x; gð Þ and
fwt gð Þ, we are interested in recovering t(x), which models the position-dependent
mismatch tolerance, a property of the Cas9 and Cpf1 protein that is independent of
sgRNA sequences, target or transfection batches. We solve the following problem,
t^ xð Þ; a^ gð Þ; x0¼ argmin
X
x;g
t x0ð Þ þ a gð Þ fmut x; gð Þ
fwt gð Þ

þ
X
l x0  xj j:
s:t: x0  xj job
The t(x) is modelled using a third-order B-spline, a continuously differentiable
function deﬁned on interval (1,20) and a gð Þ 2 R1. The optimization is solved using
gradient descent. The optimal solution t^ xð Þ is normalized to get min t^ xð Þ¼0 and
max t^ xð Þ¼1. The parameter l controls the strength of lasso, which is set to 0.3. The
parameter b represents the range of wobbling, which is set to 0.5.
Data availability. All sequencing data related to this study have been deposited in
the NCBI Sequence Read Archive at SRP099132. All other data are available from
the authors upon reasonable request.
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